Does Scripps Health Cover Eliquis?

What Is Eliquis and Why Do Cardiologists Prescribe It?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that blocks Factor Xa in the coagulation cascade. The FDA approved it in 2012 for stroke prevention in nonvalvular atrial fibrillation, and later for treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE). FDA prescribing information for apixaban is maintained at accessdata.fda.gov.

Clinical evidence that drives prescribing

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily against dose-adjusted warfarin in patients with atrial fibrillation. Apixaban reduced stroke or systemic embolism by 21% (1.27% per year vs. 1.60% per year; P<0.001) and all-cause mortality by 11% (3.52% vs. 3.94%; P=0.047). Major bleeding was also lower with apixaban (2.13% vs. 3.09% per year; P<0.001). Read the full ARISTOTLE publication in the New England Journal of Medicine.

The AMPLIFY trial (N=5,395) showed apixaban was non-inferior to conventional therapy (enoxaparin plus warfarin) for treating acute DVT and PE, with a 69% reduction in major bleeding (0.6% vs. 1.8%; P<0.001). AMPLIFY results are published in the New England Journal of Medicine.

These outcomes explain why the 2023 ACC/AHA Atrial Fibrillation Guideline gives DOACs a Class I recommendation over warfarin for most patients with nonvalvular AF. The guideline is freely accessible via the Journal of the American College of Cardiology.

Why cost and coverage still matter

Despite strong clinical support, apixaban carries no generic equivalent in the United States as of early 2025. A 30-day supply of apixaban 5 mg twice daily has a wholesale acquisition cost near $593. Insurance formulary placement therefore has a direct, measurable effect on whether patients stay adherent. A 2022 analysis in JAMA Network Open found that cost-related non-adherence to anticoagulants in AF was associated with a 1.4-fold increase in stroke hospitalization risk. Access that analysis at jamanetwork.com.

How Scripps Health Plan Formularies Are Structured

Scripps Health is both a healthcare delivery system and the sponsor of affiliated health insurance products in San Diego County. The two main insurance vehicles are Scripps Health Plan (commercial HMO/PPO) and Scripps Health Plan Medicare Advantage. Each product maintains its own formulary, and the tier placement of apixaban can differ between them.

Commercial plan tiers

On Scripps Health Plan commercial products, brand-name drugs without a generic equivalent typically land on Tier 3 (preferred brand) or Tier 4 (non-preferred brand). Tier 3 cost-sharing commonly runs $50 to $100 per 30-day supply after the deductible is met. Tier 4 cost-sharing may reach $150 to $250 or higher per fill.

Because formularies are updated annually, the exact tier for any given plan year must be verified through the Scripps Health Plan drug formulary search tool or by calling member services at the number on your insurance card. The Medicare Part D formulary is filed with the Centers for Medicare and Medicaid Services and is publicly searchable. CMS maintains the Medicare Plan Finder at medicare.gov, and drug-level formulary data is governed by CMS regulations detailed at cms.gov.

Medicare Advantage formulary rules

Scripps Health Plan Medicare Advantage enrollees follow Part D formulary rules. CMS requires all Part D plans to include at least two drugs in each therapeutic category, but brand-name DOACs frequently face prior authorization or step therapy requirements. The 2024 CMS final rule on Part D redesign did cap out-of-pocket costs for Medicare enrollees at $2,000 per year beginning in 2025, which materially reduces catastrophic-phase apixaban spending for seniors. Details of the Inflation Reduction Act Part D redesign are at cms.gov.

Prior Authorization for Eliquis at Scripps Health Plans

Prior authorization (PA) is a plan requirement that the prescribing physician obtain approval before the plan will pay for a drug. Apixaban PA criteria at most commercial and Medicare Advantage plans require the prescriber to document:

• A confirmed diagnosis (e.g., nonvalvular AF with CHA2DS2-VASc score of 2 or higher in men, or 3 or higher in women, per 2023 ACC/AHA AF guidelines)
• A clinical reason the patient cannot use warfarin or another lower-tier anticoagulant (for step-therapy plans)
• INR monitoring difficulty, documented labile INR on warfarin, or a drug-drug interaction that makes warfarin unsafe

What your cardiologist needs to submit

A complete PA submission for apixaban typically includes the office visit note documenting the diagnosis, a completed plan-specific PA form, and, for step-therapy plans, documentation of a warfarin trial or contraindication. The American College of Cardiology has published guidance noting that step therapy for anticoagulants in AF is clinically problematic because the evidence base for DOACs is independent of warfarin failure. See the ACC's position on step therapy at acc.org.

Turnaround times and urgent requests

Standard PA decisions are required within 72 hours under most state insurance laws, and urgent (expedited) decisions must arrive within 24 hours when a delay could seriously harm the patient. California Department of Managed Health Care (DMHC) rules apply to Scripps Health Plan commercial products. California DMHC independent medical review data is published at dmhc.ca.gov.

Step Therapy: When Scripps May Require You to Try Another Drug First

Step therapy means the plan requires a trial of a lower-cost drug before authorizing the prescribed agent. For anticoagulation, a plan may require warfarin first, or may accept a different DOAC on a lower tier before covering apixaban.

Clinical problems with anticoagulant step therapy

Warfarin requires regular INR monitoring, has more than 200 documented food and drug interactions, and achieves therapeutic INR only about 55 to 65% of the time in real-world practice. The 2023 ACC/AHA AF guideline states: "For patients with AF, oral anticoagulation with a DOAC is recommended in preference to VKA therapy for most patients" (Class I, Level of Evidence A). Full guideline text is available at jamanetwork.com.

Switching a stable patient from apixaban to warfarin solely to meet a step-therapy requirement introduces a period of potential under-anticoagulation during bridging, as well as increased INR monitoring burden.

Appealing a step-therapy denial

California Senate Bill 510 (enacted 2018) requires health plans to grant a step-therapy exception when the required drug is contraindicated, has been ineffective, or would cause an adverse reaction. Your cardiologist can submit a step-therapy exception request citing:

• Documented labile INR or INR monitoring difficulty in prior warfarin use
• Drug-drug or drug-disease interactions (e.g., concomitant antiplatelet therapy increasing warfarin bleeding risk)
• Patient history of warfarin-induced skin necrosis or other adverse reactions
• Clinical judgment that the delay imposed by a warfarin trial poses unacceptable stroke risk given the patient's CHA2DS2-VASc score

How Much Will You Actually Pay? Cost Scenarios

The out-of-pocket cost for apixaban depends on your specific plan, tier placement, deductible status, and benefit phase.

Commercial plan cost estimates

| Scenario | Estimated Monthly Cost | |---|---| | Tier 3, deductible met | $50 to $100 | | Tier 4, deductible met | $150 to $250 | | Deductible phase (before meeting it) | Up to $593 (full WAC) | | With BMS $10 co-pay card (commercially insured) | As low as $10 per month |

Bristol-Myers Squibb and Pfizer co-market Eliquis and offer a co-pay savings program for commercially insured patients, reducing monthly cost to as low as $10 per fill. This program does not apply to Medicare, Medicaid, or government-funded insurance. Program details are at bms.com; drug pricing context is provided by the FDA's drug pricing transparency resources at fda.gov.

Medicare Part D cost in 2025

Under the Inflation Reduction Act Part D redesign effective January 1, 2025, out-of-pocket drug spending for Medicare enrollees is capped at $2,000 per calendar year. For a Scripps Medicare Advantage enrollee on a plan where apixaban is Tier 3 with a $47 co-pay per fill, total out-of-pocket across the year would not exceed $2,000 even if the drug cost is high in the deductible phase. CMS provides an updated Part D cost-sharing explanation at cms.gov.

Patient Assistance and Manufacturer Programs

If cost remains prohibitive after insurance, three pathways may help.

Bristol-Myers Squibb Patient Assistance Foundation

The BMS Patient Assistance Foundation provides free Eliquis to uninsured and underinsured patients meeting income criteria (generally at or below 400% of the federal poverty level, which is approximately $60,240 for a single individual in 2025). Applications require physician attestation of medical need. Apply or review eligibility at bmspaf.org; federal poverty guidelines are published annually at aspe.hhs.gov.

NeedyMeds and state pharmaceutical programs

NeedyMeds.org lists additional state and nonprofit assistance programs. California does not currently have a state-specific DOAC subsidy program, but the California Department of Aging manages HICAP (Health Insurance Counseling and Advocacy Program), which can help Medicare beneficiaries identify the lowest-cost Part D plan covering apixaban. HICAP program information is at aging.ca.gov; CMS data on low-income subsidy (Extra Help) eligibility is at ssa.gov.

340B pricing at Scripps facilities

Scripps Health participates in the federal 340B Drug Pricing Program, which allows qualifying outpatient facilities to purchase covered drugs at significantly reduced prices. Eligible patients (those meeting low-income or uninsured thresholds treated at a 340B-covered entity) may access apixaban at substantially reduced cost through a Scripps-affiliated pharmacy. The Health Resources and Services Administration (HRSA) maintains the 340B program database at hrsa.gov.

Clinically Appropriate Alternatives If Coverage Is Denied

If a PA denial is upheld or cost remains unmanageable, your cardiologist will evaluate alternatives based on your specific indication.

Rivaroxaban (Xarelto)

Rivaroxaban is the only other Factor Xa inhibitor with broad DOAC indications. In some Scripps plan formularies it sits on a lower tier than apixaban, making it less expensive. The ROCKET-AF trial (N=14,264) found rivaroxaban 20 mg once daily non-inferior to warfarin for stroke prevention in AF (1.7% vs. 2.2% per year; P<0.001 for non-inferiority). ROCKET-AF results are at nejm.org. Head-to-head network meta-analyses suggest apixaban may have a modest bleeding advantage over rivaroxaban, so any switch should be individualized.

Dabigatran (Pradaxa)

Dabigatran is a direct thrombin inhibitor. RE-LY (N=18,113) showed dabigatran 150 mg twice daily reduced stroke by 34% relative to warfarin (1.11% vs. 1.69% per year; P<0.001) in AF. RE-LY data are at nejm.org. Dabigatran requires dose adjustment for renal impairment and interacts with P-glycoprotein inhibitors.

Warfarin with INR support services

Warfarin remains guideline-supported for patients with mechanical heart valves (where DOACs are contraindicated per FDA black-box warning) and for patients in whom cost is the only barrier. Scripps Health operates anticoagulation management clinics in San Diego County that provide point-of-care INR testing, reducing the monitoring burden. Warfarin prescribing and INR management guidance is covered in the ACCP Antithrombotic Guidelines archived at chest.pubpubs.chestnet.org and referenced via pubmed.ncbi.nlm.nih.gov.

What to Do If Your Scripps Plan Denies Eliquis Coverage

A denial is not a final answer. California law and federal Part D rules provide multiple appeal layers.

Step 1: Internal appeal

File a first-level appeal within 180 days of the denial notice (60 days for Medicare Part D). Submit your cardiologist's clinical letter, relevant trial data supporting apixaban over warfarin for your specific condition, and any documentation of prior intolerance to the required step-therapy drug. The plan must respond within 30 days for standard appeals or 72 hours for expedited. California DMHC appeal rights are outlined at dmhc.ca.gov.

Step 2: Independent Medical Review

If the internal appeal fails, California law requires the plan to offer an Independent Medical Review (IMR) through DMHC. An independent physician reviewer evaluates medical necessity without financial conflict. IMR decisions are binding on the plan. Approximately 50 to 60% of anticoagulant IMR requests are overturned in favor of the patient when properly documented.

Step 3: Medicare redetermination (Medicare Advantage)

For Medicare Advantage denials, the appeals hierarchy runs: plan redetermination, Qualified Independent Contractor (QIC) reconsideration, Office of Medicare Hearings and Appeals (OMHA), Medicare Appeals Council, then federal district court. CMS describes all five levels of Medicare appeals at medicare.gov.

The HealthRX clinical team has developed a four-step Eliquis Coverage Decision Framework for use at the point of care. The framework maps CHA2DS2-VASc score, creatinine clearance, and formulary tier against the optimal initial PA strategy, helping prescribers choose between a standard PA, a step-therapy exception, or an immediate appeal based on patient-specific data rather than blanket plan rules.

Documentation Checklist for Your Prescribing Physician

Your cardiologist or internist will have the best chance of obtaining apixaban coverage when the chart contains:

• A 12-lead ECG or Holter report confirming nonvalvular atrial fibrillation (or imaging/Doppler confirming DVT/PE)
• Calculated CHA2DS2-VASc score with component breakdown
• Current renal function (serum creatinine, eGFR, or CrCl by Cockcroft-Gault) because CrCl <25 mL/min is a study exclusion threshold for apixaban
• A list of current medications flagging interactors with warfarin (amiodarone, antibiotics, antifungals, SSRIs)
• Prior anticoagulant history, including warfarin INR logs if available
• A dated office note explicitly stating why apixaban is preferred over warfarin for this patient

The ACC provides a DOAC prescribing checklist at acc.org.

Special Populations: Dose Adjustments and Coverage Implications

Apixaban dosing changes in specific populations, and incorrect dosing may trigger a PA flag.

Renal impairment

Apixaban does not require dose adjustment until CrCl drops below approximately 25 mL/min, where data are limited. For patients on dialysis, the FDA label notes limited data but the drug is sometimes used off-label at reduced doses. FDA apixaban prescribing information is at accessdata.fda.gov.

Atrial fibrillation dose reduction criteria

The FDA-approved dose reduction for AF is apixaban 2.5 mg twice daily when a patient meets at least two of three criteria: age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher. Prescribing 5 mg twice daily for a patient who meets two of three criteria may trigger an automated PA flag from the plan's pharmacy benefit manager. Documenting why the standard 5 mg dose applies (e.g., only one criterion is met) avoids unnecessary delays.

Post-surgical prophylaxis

For DVT prophylaxis after hip or knee replacement, apixaban 2.5 mg twice daily for 12 days (knee) or 35 days (hip) is FDA-approved. Some plans require PA even for this short-course indication. The ADVANCE-3 trial (N=5,407) showed apixaban reduced total VTE and VTE-related death by 69% compared with enoxaparin after hip replacement. ADVANCE-3 is published at nejm.org.